IMNN

Imunon, Inc. (IMNN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA therapeutics. Its lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer currently in Phase 3 development (OVATION 3). The company also has a vaccine modality, PlaCCine, with a Phase 1 candidate (IMNN-101) for COVID-19. The company is classified as a smaller reporting company and a non-accelerated filer.

Key Financial Metrics

Cash Flow (YTD 2025): Net cash used in operating activities was $5.80 million. Net cash used in investing activities was $0.28 million. Net cash provided by financing activities was $4.93 million, driven by equity sales and warrant exercises.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 44.8% in Q2 2025 compared to Q2 2024 ($2.77M vs. $5.01M). YTD 2025 expenses were down 31.0% compared to YTD 2024.
• R&D Spend: Research and development expenses dropped significantly, primarily due to reduced clinical costs for the PlaCCine vaccine program and the OVATION program, offset slightly by increased non-clinical R&D for OVATION.
• Financing Activity: The company raised approximately $4.93 million in net cash through financing activities in the first six months of 2025, including a private placement in May 2025 and warrant exercises. In contrast, there were no financing proceeds in the same period in 2024.
• Investment Income: Investment income decreased to $27,000 in Q2 2025 from $225,000 in Q2 2024, reflecting lower cash balances and interest rates.

Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. With $4.73 million in cash and a burn rate of approximately $5.8 million over six months, the company requires additional capital to fund operations for the next 12 months.
• Nasdaq Compliance: The company received a delisting notice from Nasdaq in May 2025 for failing to meet the minimum bid price ($1.00) and minimum stockholders' equity ($2.5 million) requirements. To address this, the company effected a 15-for-1 reverse stock split on July 25, 2025, and approved a 15% stock dividend in July 2025.
• Clinical Progress:
  • IMNN-001 (Ovarian Cancer): Positive Phase 2 data (OVATION 2) showed a 13-month increase in median overall survival. The company has FDA alignment for the Phase 3 OVATION 3 trial and has begun site initiation.
  • IMNN-101 (COVID-19): Phase 1 data demonstrated safety and immunogenicity, with durable neutralizing antibody titers at six months.
• Capital Strategy: The company plans to raise funds through its At-The-Market (ATM) program, private placements, or strategic partnerships. There is no assurance that funding will be available on acceptable terms.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $4.73 million cash balance against the current burn rate and the timeline for the next capital raise.
• Nasdaq Status: Confirm the company's current listing status on Nasdaq following the July 2025 reverse stock split and stock dividend.
• Phase 3 Timeline: Monitor the enrollment progress and estimated costs for the OVATION 3 Phase 3 trial, which is critical for future valuation.
• Dilution Risk: Assess the impact of recent and potential future equity issuances (including the 15% stock dividend and warrant exercises) on existing shareholder ownership.
• Going Concern: Review the specific terms of any new financing agreements or strategic partnerships announced post-filing.